Literature DB >> 9796972

Polymorphism within the cyclin D1 gene is associated with prognosis in patients with squamous cell carcinoma of the head and neck.

C Matthias1, K Branigan, V Jahnke, K Leder, J Haas, J Heighway, P W Jones, R C Strange, A A Fryer, P R Hoban.   

Abstract

We have examined the correlation of a frequent A/G polymorphism within exon 4 of the cyclin D1 gene (CCND1) with genetic susceptibility and clinical outcome in 384 patients with squamous cell carcinoma (SCC) of the head and neck. CCND1 genotype frequencies were similar in the cases and 191 controls. Furthermore, the CCND1 genotype was not associated with susceptibility to SCC of the larynx, pharynx, or oral cavity. The influence of the CCND1 genotype on clinical outcome was also assessed. We found no correlation between genotype and tumor size (T1-T4), the involvement of nodes at presentation, or patient age and gender. However, the distribution of CCND1 genotypes in cases with poorly differentiated tumors was significantly different to that in patients with well-/moderately differentiated tumors (P = 0.016; chi2(2) = 8.71). Homozygosity for CCND1*G (GG genotype) was associated with poorly differentiated tumors (G3). We used Cox's proportional hazards model to investigate the influence of the CCND1 genotype on disease-free interval. CCND1 GG was associated with reduced disease-free interval [P = 0.001; hazard ratio (HR) = 2.95; 95% confidence interval (CI) = 1.54-5.63]. This remained significant after correction for tumor differentiation (P = 0.013; HR = 2.34; 95% CI = 1.2-4.6) and tumor stage (P = 0.005; HR = 2.64; 95% CI = 1.34-5.19). Analysis of the data from patients with tumors at different sites showed that the CCND1 GG genotype was associated with reduced disease-free interval in laryngeal (P = 0.004; HR = 3.63; 95% CI = 1.44-8.83) and pharyngeal (P = 0.006; HR = 3.48; 95% CI = 1.43-8.46) tumors. This is the first report of an association between CCND1 polymorphism and prognosis in SCC of the head and neck. These data show that the CCND1 GG genotype is an independent prognostic indicator of disease-free interval and supports initial observations in non-small cell lung cancer, that polymorphism within CCND1 influences tumor behavior.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9796972

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Squamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.

Authors:  Wusheng Yan; Ignacio I Wistuba; Michael R Emmert-Buck; Heidi S Erickson
Journal:  Am J Cancer Res       Date:  2011-01-01       Impact factor: 6.166

2.  CCND1 G870A polymorphism and risk for head and neck cancer: a meta-analysis.

Authors:  Chunbo Tang; Zhanwei Wang; Jinhua Yu; Yunong Wu; Zhijun Zhu; Ning Chen
Journal:  Med Oncol       Date:  2010-05-05       Impact factor: 3.064

3.  Influential factors on tumor recurrence in head and neck cancer patients.

Authors:  Christoph Matthias; Ulrich Harréus; Richard Strange
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-07-08       Impact factor: 2.503

4.  Effects of common germ-line genetic variation in cell cycle genes on ovarian cancer survival.

Authors:  Honglin Song; Estrid Hogdall; Susan J Ramus; Richard A Dicioccio; Claus Hogdall; Lydia Quaye; Valerie McGuire; Alice S Whittemore; Mitul Shah; David Greenberg; Douglas F Easton; Susanne Kruger Kjaer; Paul D P Pharoah; Simon A Gayther
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

5.  Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.

Authors:  Xuwei Hou; Sili Wang; Yuling Zhou; Ziliang Xu; Yao Zou; Xiaofan Zhu; Mingzhe Han; Tianxiang Pang; Zhong Chao Han
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

6.  Association of DNA repair and cell cycle gene variations with breast cancer risk in Northeast Indian population: a multiple interaction analysis.

Authors:  Mishi Kaushal Wasson; Pradeep Singh Chauhan; L C Singh; Dheeraj Katara; Jagannath Dev Sharma; Eric Zomawia; Amal Kataki; Sujala Kapur; Sunita Saxena
Journal:  Tumour Biol       Date:  2014-03-07

7.  Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.

Authors:  Malgorzata Rydzanicz; Pawel Golusinski; Daniela Mielcarek-Kuchta; Wojciech Golusinski; Krzysztof Szyfter
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-10-29       Impact factor: 2.503

Review 8.  Regulation of chemoresistance via alternative messenger RNA splicing.

Authors:  Scott T Eblen
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

9.  Cyclin D1 polymorphism and expression in patients with squamous cell carcinoma of the head and neck.

Authors:  S L Holley; G Parkes; C Matthias; U Bockmühl; V Jahnke; K Leder; R C Strange; A A Fryer; P R Hoban
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

10.  Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome.

Authors:  E K A Millar; J L Dean; C M McNeil; S A O'Toole; S M Henshall; T Tran; J Lin; A Quong; C E S Comstock; A Witkiewicz; E A Musgrove; H Rui; L Lemarchand; V W Setiawan; C A Haiman; K E Knudsen; R L Sutherland; E S Knudsen
Journal:  Oncogene       Date:  2009-03-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.